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the positive response ratio was calculated by dividing the number of patients who fol-
lowed the pharmacist advice to total number of patients to whom the advice was pro-
vided. The cost saving per patient per year was determined from available literature. 
RESULTS: A total of 180 interventions were made by the pharmacists. Pattern manage-
ment (100 cases, 55.5%) and alerting physician of an abnormal A1c (61, 33.8%) were
the most frequent. The most accepted interventions were glucometer training (2 cases, 
100%), advising to correct hypoglycemic/hyperglycemic episodes (12, 66.7%), and 
instructing on the proper use of their injectables (5, 60.0%). Cost savings of $1914/
patient/year were estimated as a result of the 4th and 5th intervention. Also, interven-
tions 1, 2 and 3 resulted in cost-saving of $1161, $ 1203, and $1531 per patient per 
year respectively. CONCLUSIONS: Our model showed that pharmacist interventions 
can result in signiﬁ cant cost savings among diabetic patients.
HM3
IMPACT OF A SPECIALTY CARE MANAGEMENT PROGRAM ON
MEDICATION ADHERENCE AND HEALTH CARE UTILIZATION AMONG
NON–ELDERLY ADULTS WITH MULTIPLE SCLEROSIS
Yu J, Tan H, Singer J
HealthCore, Inc, Wilmington, DE, USA
OBJECTIVES: To evaluate the impact of a specialty care management program (Pre-
cisionRx Pharmacy Management) on medication adherence, risk of hospitalization, 
and costs of care among MS patients. METHODS: This study was a retrospective 
analysis of administrative claims from 13 geographically dispersed US commercial
health plans. Patients aged 18–64 years with q2 claims of MS diagnosis and q1 MS
medications (Interferon beta-1a, Interferon beta-1b, and Glatiramer acetate) from
January 1, 2004 and April 30, 2008 were identiﬁ ed. For patients enrolled in Preci-
sionRx program (managed), index date was deﬁ ned as the program participation date; 
for other patients (non-managed), index date was randomly assigned through Monte
Carlo simulation with regard to the managed patients. At least 12 months of continu-
ous eligibility pre- and post- index was required. Outcome metrics included medication 
adherence (measured by medication possession ratio (MPR)), risk of MS-related
hospitalization, and MS-related costs. Multivariate analyses were performed to adjust
for baseline demographics, baseline health care costs, and clinical characteristics. 
RESULTS: Among 3862 patients identiﬁ ed, 79% were managed and 21% were non-
managed patients. The multivariate analysis showed that compared with the non-
managed group, the managed group had 0.21 higher MPR (95% CI: 0.19–0.23, p 
0.001), were less likely to be hospitalized for MS (adjusted odds ratio: 0.53 (0.40–
0.70), p  0.001), and had 25% higher MS-related costs (95% CI: 20%-31%, p 
0.001), controlling for other covariates. The relatively larger increase in MS-related 
costs from pre-index to post-index among the managed group (median: $3791 vs. 
$2277) was primarily driven by larger increase in their pharmacy costs (median: $3968 
vs. $1885). CONCLUSIONS: Overall, this specialty care management program was 
associated with better medication adherence and lower risk of MS-related hospitaliza-
tion. The associated higher MS-related costs among the managed group could be
explained by their relatively larger increase in pharmacy costs, as expected due to
better medication adherence and high costs of MS medication.
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THE IMPACT OF A PHARMACIST–PROVIDED TELEPHONE MEDICATION
THERAPY MANAGEMENT PROGRAM ON MEDICATION AND HEALTH–
RELATED PROBLEMS, MEDICATION ADHERENCE, AND TOTAL DRUG
COSTS AMONG MEDICARE BENEFICIARIES: A 6–MONTH FOLLOW–UP
Moczygemba LR1, Barner JC2, Lawson KA2, Brown CM2, Gabrillo E3, Godley PJ4, 
Johnsrud M2
1Virginia Commonwealth University, Richmond, VA, USA, 2University of  Texas at Austin, 
Austin, TX, USA, 3Scott and White Health Plan, Temple, TX, USA, 4Scott and White Health 
System, Temple, TX, USA
OBJECTIVES: To determine if differences existed between the intervention group 
[after participating in a pharmacist-provided telephone medication therapy manage-
ment (PPMTM) program] and the control group in: 1) Medication/health-related 
problems (MHRPs); 2) Medication adherence; and 3) Total Part D drug costs. 
METHODS: This quasi-experimental study of Part D beneﬁ ciaries from a Texas health 
plan used the Andersen Model as its theoretical framework. Predisposing factors were 
age, gender, and race; need factors were number of medications, number of chronic 
diseases and medication regimen complexity. The intervention and control groups
were matched on number of medications and number of chronic diseases. The health 
behavior was PPMTM participation. Outcomes were changes in: 1) Number of 
MHRPs; 2) Medication adherence using medication possession ratio (MPR); and 3)
Total drug costs. Multivariate regression was used for group comparisons of outcomes.
RESULTS: The intervention (n  60) and control (n  60) groups were not statistically 
different in predisposing or need factors except for gender (intervention  51.7% male; 
control  28.3% male; p  0.009). At baseline, 4.8 (o2.7) MHRPs were identiﬁ ed in 
the intervention group and 9.2 (o2.9) in the control group. At the 6-month follow-up, 
2.5 (o2.0) and 7.9 (o3.0) MHRPs remained, respectively. Multivariate regression
revealed that the intervention group had signiﬁ cantly more MHRPs resolved (p 
0.0003) when compared to the control group, while controlling for predisposing and 
need factors. There were no other signiﬁ cant predictors of MHRP resolution, Analyses 
showed no signiﬁ cant predictors of change in MPR or total drug costs from baseline
to 6-month follow-up. CONCLUSIONS: A telephone MTM program was effective in
resolving MHRPs among Medicare beneﬁ ciaries; however, no signiﬁ cant differences 
existed between the intervention and control groups in medication adherence and total 
drug costs.
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PREDICTORS OF ENROLLMENT IN MEDICARE PART D: 
ARE BENEFICIARIES RATIONAL?
Lines LM1, Menzin J1, Lang K1, Korn JR1, Neumann PJ2
1Boston Health Economics, Inc, Waltham, MA, USA, 2Tufts Medical Center, Boston, MA, USA
OBJECTIVES: The initiation of Medicare Part D in 2006 offers an ideal opportunity
to study real-world decision-making and the role of adverse selection and other factors 
in insurance enrollment. Our objective was to identify predictors of Part D enroll-
ment among individuals with a range of health conditions and insurance designs. 
METHODS: The sample included all individuals in both the 2005 and 2006 Medical 
Expenditure Panel Survey (MEPS) datasets who were enrolled in Medicare, but not 
Medicaid, as of December 2005. A multivariate logistic regression was used to assess 
the effects of sociodemographics, health status, 2005 supplemental insurance cover-
age, and 2005 person-level out-of-pocket (OOP) drug expenditures on the likelihood 
of enrolling in Part D in 2006. MEPS sample weights were used to calculate standard 
errors. RESULTS: Out of 1,436 persons who met inclusion criteria, 657 (45.4%) 
enrolled in Part D during 2006. Compared to the no-Part D group, the Part D group 
was slightly older, had more non-whites, rural residents, and unmarried individuals,
and was slightly less educated and poorer. The Part D group had more beneﬁ ciaries
with Medigap coverage only (17.2% vs. 5.7%), fewer with employer-based coverage 
only (18.3% vs. 37.1%), and more with no private supplemental insurance (46.1% 
vs. 32.1%). In multivariate analyses, signiﬁ cant positive predictors of Part D enroll-
ment were having Medigap supplemental insurance only (OR: 1.99; 95% CI: 1.25–
3.19) and OOP drug expenditures q$2500 in 2005 (OR: 1.58; 95% CI: 1.03–2.41).
Most beneﬁ ciaries with employer-based coverage in 2005 maintained that coverage in
2006 (91.8%). CONCLUSIONS: Based on ﬁ rst-year data, fears of only the sickest
beneﬁ ciaries enrolling in Part D and employers withdrawing drug beneﬁ ts to retirees
seem to have been unwarranted. Existing coverage and high prior drug spending drove
the decision to enroll in Part D in what appears to have been a rational way.
MD6
PREDICTORS OF UTILIZATION OF ACE INHIBITORS AND
ANGIOTENSIN II RECEPTOR BLOCKERS AMONG MEDICARE PART D
ENROLLEES WITH DIABETES
Yang Y, Thumula V, Pace PF, Banahan BF, Wilkin NE, Lobb WB
University of Mississippi, University, MS, USA
OBJECTIVES: The objectives were to describe angiotensin-converting enzyme inhibi-
tors (ACEI) and angiotensin II receptor blockers (ARB) use among Medicare Part D 
enrollees with diabetes and to identify patient characteristics that predict ACEI/ARB
utilization. METHODS: This is a longitudinal retrospective cohort study. The study 
sample included Medicare Part D enrollees from 6 states (Alabama, California, 
Florida, Mississippi, New York, and Ohio) aged 18 years or older with the diagnosis
of diabetes. Medicare Part D claims data for the ﬁ rst 6 months of 2006 were evaluated
for any utilization of ACEI/ARB. The outcome of interest was the percentage of at
least one claim for an ACEI or an ARB during the ﬁ rst half of 2006. RESULTS: A
total of 1,888,682 patients met our inclusion criteria. Mean age (oSD) was 71.6 
(o11.6) years, 59.5% were female, and 66.4% were white. Approximately 58.9%,
5.8%, 0.5% had coexisting hypertension, nephropathy, and hypertension  nephropa-
thy. Overall, 56.9% were receiving ACEI/ARB therapy. Logistic regression indicated 
that patients with coexisting hypertension  nephropathy and hypertension were 72%
and 36% more likely to use ACEI/ARB compared to patients without hypertension
and/or nephropathy. However, patients with nephropathy were 24% less likely to
receive ACEI/ARB therapy. Females, older patients, and patients of nonwhite races 
were also more likely to use ACEI/ARB. Patients with myocardial infarction, sleep 
apnea, coronary artery disease, retinopathy or heart failure were more likely to have 
used ACEI/ARB, while the opposite was true for those with hypercholesterolemia, 
peripheral vascular, cerebrovascular, or chronic obstructive pulmonary diseases. All 
results were statistically signiﬁ cant at P  .0001 level. CONCLUSIONS: Less than
60% of Medicare Part D enrollees with diabetes received ACEI/ARB therapy. Several
patient characteristics can predict ACEI/ARB use. Opportunities exist for quality-
improvement interventions that could increase the outcomes for high-risk patients.
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DOES MEDICARE HAVE AN IMPLICIT COST–EFFECTIVENESS 
THRESHOLD?
Chambers J1, Neumann PJ2, Buxton MJ3
1Mapi Values, Boston, MA, USA, 2Tufts Medical Center, Boston, MA, USA, 3Brunel University, 
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OBJECTIVES: Despite the huge cost of the program, the Centers for Medicare and 
Medicaid Services (CMS) maintains that cost-effectiveness is not considered in national 
coverage determinations (NCDs) for medical technologies. Our objective was to assess 
the cost-effectiveness of technologies and interventions that are the subject of Medicare 
NCDs in order to investigate whether an implicit cost-effectiveness threshold exists. 
In addition, we explored whether CMS have cited cost-effectiveness evidence in NCDs. 
METHODS: We reviewed NCD decision memos from 1999 through 2007 (n  103). 
A literature review was conducted for each coverage decision to ﬁ nd relevant economic
evaluations. The economic evaluation that best represented each coverage decision 
was included in a review of the cost-effectiveness of medical technologies considered 
in NCDs. RESULTS: Sixty-four coverage decisions were identiﬁ ed from 103 decision 
memos. Fifty were associated with a positive coverage decision and 14 with a 
A16 Abstracts
non-coverage decision. Of the positive decisions, 22 were associated with an economic 
evaluation that estimated the medical intervention to be dominant (costs less and more
effective than the alternative), 8 with an incremental cost-effectiveness ratio (ICER)
of less than $50,000, 8 with an ICER greater than $50,000 but less than $100,000, 
and 8 with an ICER greater than $100,000 (2008 USD). In four of the positive cover-
age decisions the intervention was dominated (costs more and was less effective than 
the alternative). Of the non-coverage decisions, 3 interventions were estimated to be
dominant, 6 were associated with an ICER less than $30,000, one with an ICER of 
approximately $200,000, and four were dominated. Fourteen decision memos cited 
or discussed cost-effectiveness information. CONCLUSIONS: CMS is covering a
number of interventions that do not appear to be cost-effective by traditional stan-
dards. While we identiﬁ ed several instances where cost-effectiveness evidence was cited 
in NCDs, we found no clear evidence of an implicit constant ﬁ xed cost-effectiveness 
threshold.
MD8
OUT OF POCKET PSYCHOTROPIC PRESCRIPTION BURDEN ON
ELDERLY MEDICARE BENEFICIARIES BEFORE AND AFTER THE
IMPLEMENTATION OF MEDICARE PART D
Chen H1, Chaudhari S2, Aparasu R1, Johnson M1
1University of Houston, Houston, TX, USA, 2Xcenda, Palm Harbor, FL, USA
OBJECTIVES: To examine the out of pocket spending on psychotropic medications 
by elderly Medicare beneﬁ ciaries before and after the implementation of Medicare
Part D. METHODS: The effect of Part D was measured using 2005–2006 pharmacy
claims data from one of the largest retail pharmacy chains in the United States. The 
psychotropic medications examined in this study included antidepressants, antipsy-
chotics benzodiazepines and barbiturates. In addition to evaluating overall out of 
pocket burden in 2005 and 2006, the study examined out of pocket burden among 
Medicare-Medicaid dual eligible beneﬁ ciaries, non-dual Part D enrollees, and those
who did not enroll in Medicare Part D. The out of pocket burden was calculated as
a percentage of total pharmacy reimbursement involving elderly persons 65 years or 
older. RESULTS: The proportion of out of pocket expenditures in total pharmacy 
reimbursement dropped 7.62% (from 40.43% to 32.81%) for antidepressants, 6.24% 
for antipsychotics (from 27.82% to 21.58%), but increased 12.15% for benzodiaze-
pines (from 62.64% to 74.79%), and 9% (from 71.96% to 80.56%) for barbiturates.
Dual eligible beneﬁ ciaries were the group most severely affected by the policy change. 
For dual eligible beneﬁ ciaries who were on any of the four drug categories, their yearly
out of pocket expense increased extensively. The most dramatic change was observed 
in dual eligibles using benzodiazepines. Their out of pocket expenditure increased by
around 12 folds from 2005 to 2006. Non-dual Part D enrollees beneﬁ ted the most
from the new drug policy. The most signiﬁ cant cost saving was found in non-dual Part 
D enrollees who were on antidepressants (from 62.23% to 32.97%) and antipsychot-
ics (from 55.24% to 38.30%). CONCLUSIONS: The implementation of Part D was 
associated with reduced out of pocket psychotropic prescription burden on non-dual
Part D enrollees, however, out-of –pocket burden on the dual eligible beneﬁ ciaries
severely increased.
PODIUM SESSION IV: MUSCULAR–SKELETAL DISORDERS – 
Outcomes Research
MS1
ASSESSMENT OF PREFERENCE AND SATISFACTION WITH A 
WEEKLY ORAL TABLET VERSUS A 6–MONTH SUBCUTANEOUS 
INJECTION FOR THE TREATMENT OF OSTEOPOROSIS
Kendler DL1, Gold DT2, Horne R3, Borenstein J4, Varon SF4, Man HS4, Siddhanti S4, 
Satram-Hoang S4, Macarios D4, Bone HG5
1Clinical Research Centre, Vancouver, BC, Canada, 2Duke University Center for the Study of 
Aging and Human Development, Durham, NC, USA, 3The School of Pharmacy, University of 
London, London, UK, 4Amgen Inc, Thousand Oaks, CA, USA, 5Michigan Bone and Mineral
Clinic, Detroit, MI, USA
OBJECTIVES: We compared patient preference and satisfaction between two osteo-
porosis medications: alendronate (ALN 70 mg tablets) taken orally once weekly (QW)
and denosumab (DMAb 60 mg; investigational agent) injected subcutaneously (SC) 
every 6 months (Q6M). METHODS: Preference and satisfaction were evaluated as
part of a phase 3, double-blind, double-dummy study to determine the effects of tran-
sitioning subjects from ALN to DMAb. Postmenopausal women q55 with a lumbar 
spine or total hip T-score a2.0 and q4.0 who were receiving ALN therapy for q6 
months were eligible. After a 1-month ALN run-in phase, subjects were randomized
to treatment with continued ALN QW  placebo injection SC Q6M or DMAb SC
Q6M  QW placebo tablet. At study conclusion, subjects completed a 34-item ques-
tionnaire. Pre-determined endpoints of preference and satisfaction were measured by 
asking subjects to choose the tablet, the injection, or neither, in response to questions 
on preference (“Which do you prefer?”) and satisfaction (“With which frequency of 
administration have you been more satisﬁ ed?”). RESULTS: The subjects (n  251 ALN,
n  253 DMAb) had a mean age of 67.6 years and a median length of prior bisphos-
phonate use of 36 months (range 6 to 192). 483 (95.8%) women took the questionnaire
(240-ALN, 243-DMAb). Of the subjects who responded to the question on preference 
(240-ALN, 240-DMAb) or satisfaction (237-ALN, 242-DMAb), signiﬁ cantly more 
subjects preferred a 6-month injection vs. a weekly oral tablet (ALN:66%-Q6M injec-
tion, 19%-QW tablet, 15%-neither, p  0.0001; DMAb:70%-Q6M injection, 19%-
QW tablet, 12%-neither, p  0.0001) and signiﬁ cantly more subjects reported greater 
satisfaction with the frequency of 6-month vs. weekly dosing (ALN:68%-Q6M injec-
tion, 19%-QW tablet, 14%-neither, p  0.0001; DMAb:70%-Q6M injection, 16%-
QW tablet, 14%-neither, p  0.0001). CONCLUSIONS: A preference for and a greater 
satisfaction with a 6-month injection vs a weekly oral tablet was demonstrated in sub-
jects previously receiving and tolerating ALN therapy.
MS2
COMBINING THE SF–36 PHYSICAL FUNCTION SCALE AND THE
HEALTH ASSESSMENT QUESTIONNAIRE TO IMPROVE MEASUREMENT
OF PHYSICAL FUNCTION RHEUMATOID ARTHRITIS (RA): RESULTS: 
FROM THE PREMIER STUDY
Hammond G1, Yarlas A1, Kosinski M1, Roy S2, Cifaldi M2
1QualityMetric Incorporated, Lincoln, RI, USA, 2Abbott Laboratories, Abbott Park, IL, USA
OBJECTIVES: RA clinical studies using the SF-36 Physical Function (PF) scale and 
Health Assessment Questionnaire (HAQ) have identiﬁ ed limitations in each instru-
ment’s sensitivity across the full range of disease severity. Item Response Theory (IRT) 
estimates were used to develop a composite of both instruments (PF–HAQ) to provide
a more sensitive measure of physical health. METHODS: Data for 799 patients from
a 2-year randomized control study of adalimumab in early RA (3 years) were 
employed. Patients received adalimumab plus methotrexate; adalimumab monother-
apy; or methotrexate monotherapy. Composite PF–HAQ scores were compared indi-
vidually with PF and HAQ using 1) comparison of ﬂ oor and ceiling effects; 2) 
ANCOVA models with ACR criteria classiﬁ cation or treatment as factors (covariates: 
sex, age, BMI); and 3) receiver operating characteristics (ROC) analyses using ACR50
criteria as a gold standard. RESULTS: At baseline, 6.2% of patients were at ﬂ oor for
the PF. At endpoint, 37.7% and 14.2% of HAQ and PF scores, respectively, were at
ceiling. IRT scores, by deﬁ nition, have no ceiling or ﬂ oor. Signiﬁ cant differences across
treatment groups were obtained (F [2526]  12.21, 7.48, 3.02, p  0.001 for all com-
parisons). PF–HAQ had signiﬁ cantly more power than either individual scale to detect 
treatment differences (F-statistic ratios of PF–HAQ with PF and HAQ were 1.6 and 
4.0, respectively). PF–HAQ was better than PF at detecting differences in endpoint
ACR criteria (F-statistic ratio for PF–HAQ to PF was 1.28). ROC analyses indicated 
that PF–HAQ provided better measurement precision (p  0.001) vs. PF and equiva-
lent/better precision vs. HAQ (p  0.14) (AUC: PF 0.80, 95% CI: 0.79–0.81; HAQ: 
0.83 [0.82–0.85]; PF–HAQ: 0.84 [0.83–0.85]). CONCLUSIONS: Combining PF and 
HAQ measures into a single measure eliminated ﬂ oor/ceiling effects, and provided 
greater efﬁ ciency in discriminating treatment effects, as well as greater sensitivity vs. 
common diagnostic criteria.
MS3
THE IMPACT OF COMPLIANCE WITH BIOLOGIC THERAPY ON
CLINICAL OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS
Tang B1, McKenzie RS1, Freedman D2, Wagner S2, Piech CT1
1Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 2Consumer Health Sciences
International, Princeton, NJ, USA
OBJECTIVES: To assess the impact of compliance with biologic therapies on clinical
measures, including symptoms, quality of life (QOL), and medical resource use in 
rheumatoid arthritis (RA) patients. METHODS: Patient-reported data were collected
from the 2008 Rheumatoid Arthritis Patient Study, an Internet survey of RA patients. 
Clinical measures and medical resource use (number of surgeries, emergency room 
and physician visits, and hospitalizations within six months) were compared among 
three groups: patients who used biologics before but discontinued; patients who cur-
rently use biologics but skipped doses within the last 12 months; and patients who 
currently use biologics without skipping. Symptoms included morning stiffness, 
fatigue, and pain scores measured on a Likert scare from zero (no symptoms) to 10 
(severe symptoms). QOL was measured by the mental component summary (MCS) 
and physical component summary (PCS) of the Health Survey Short Form (SF-36).
RESULTS: Of 2,048 respondents, 475 (23.2%) used biologic therapies, 74.3% were
female, and the average age was 51.9 years. The average duration of RA was 11.9
years, with 20.0% reporting severe disease. Among patients who used biologics, 148
(31.2%) patients discontinued and 80 (16.8%) patients reported skipping doses in the
last 12 months. Compared to the groups who discontinued, or skipped biologic doses, 
the current users who did not skip had the best symptom and QOL scores: morning 
stiffness (6.51, 5.91, 5.77), fatigue (7.00, 6.96, 6.23), pain (6.51, 6.18, 5.71), MCS
(38.0, 41.7, 41.9), and PCS (30.4, 29.2, 32.8) (all P  0.05). There were no statistical 
differences in medical resource use except physician visits, which were signiﬁ cantly 
lower in current users who did not skip doses. CONCLUSIONS: Patients who were 
compliant with their biologic therapy had better outcomes compared with patients
who discontinued or skipped doses. Compliance with biologic therapy is an important
factor optimizing effective treatment of RA.
MS4
SOCIETAL COST OF RHEUMATOID ARTHRITIS (RA) IN THE UNITED
STATES: METHODOLOGY FOR INCORPORATING INTANGIBLE COSTS
Birnbaum H1, Pike C1, Kaufman R1, Marynchenko M2, Kidolezi Y1, Cifaldi M3
1Analysis Group, Inc, Boston, MA, USA, 2Analysis Group, Inc, Montreal, QC, Canada, 3Abbott
Laboratories, Abbott Park, IL, USA
OBJECTIVES: Methods have been well-established to estimate the excess amount of 
health care services and work loss costs of RA and, to a lesser extent, caregiver costs. 
To estimate the comprehensive societal cost of RA, we assessed intangible costs associ-
ated with functional disability/quality of life and mortality legal system jury award
